Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). (Q37814691)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

enzyme replacement therapy

17 January 2020

main subject

0 references

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Derralynn A Hughes

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Gabor E Linthorst

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Carla E M Hollak

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Arndt Rolfs

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christoph Wanner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Atul Mehta

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

European Medicines Agency

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

30 November 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

Molecular Genetics and Metabolism

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

99-102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21123099%20AND%20SRC:MED&resulttype=core&format=json

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

Carbamazepine in Fabry's disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2010.11.155